Supplemental material
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 19, 2019 - Issue 2
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Source:
Ovid Technologies (Wolters Kluwer Health)
Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Source:
The Authors. Published by Elsevier Inc.
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
Source:
American College of Physicians
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Source:
Elsevier BV
Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.
Source:
The Authors. Published by Elsevier Inc.
Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
Source:
Academy of Managed Care Pharmacy
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation
Source:
Georg Thieme Verlag KG
Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation.
Source:
Hindawi Limited
National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study
Source:
American Medical Association (AMA)
Additional Events in the RE-LY Trial
Source:
Massachusetts Medical Society
A Report From the American Heart Association
Source:
Ovid Technologies (Wolters Kluwer Health)
Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin
Source:
Ovid Technologies (Wolters Kluwer Health)
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Source:
Ovid Technologies (Wolters Kluwer Health)
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Source:
Public Library of Science (PLoS)
Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population
Source:
Elsevier BV
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
Source:
Ovid Technologies (Wolters Kluwer Health)
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
Source:
American Heart Association, Inc., the American College of Cardiology Foundation, and the Heart Rhythm Society. Published by Elsevier Inc.
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.
Source:
Springer Science and Business Media LLC
Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation
Source:
Informa Healthcare
Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis
Source:
Elsevier BV
Linking provided by
